The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of the Oncotype DX recurrence score pathology-clinical (RSPC) on the predicted recurrence risk for node negative breast cancer patients: A cancer center experience.
Barbara A. Wexelman
No relevant relationships to disclose
Alexander Gallagher
No relevant relationships to disclose
Barbara L. Smith
No relevant relationships to disclose
Steven J. Isakoff
No relevant relationships to disclose